- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03983018
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
Rituximab - Immunotherapy for Schizophrenia Spectrum Disorder in Adults: An Open Pilot Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Immunological factors may be determinants for some psychiatric disorders, thus immunomodulation may be helpful. Rituximab (antibodies against CD20, cluster of differentiation), a standard treatment for multiple sclerosis, is an anti-inflammatory drug, hitherto not tested for psychiatric disorders.
The aim of this study is to investigate whether the psychiatric symptoms of treatment-resistant adult psychiatric patients, diagnosed with schizophrenia spectrum disorder (SSD), are significantly improved after treatment with rituximab. Our purpose is to implement recent insights from "Immunopsychiatry" to find efficacious, but still tolerable treatment for these patients.
This is a single-site, 20-week, open pilot, add-on treatment as usual, trial, where the patients will be followed for 1 year.
Rituximab will be administered with one single dose of 1000 mg. Investigators will analyse inflammatory and metabolic biomarkers in relation to the primary outcome, treatment response (defined as clinically relevant reduction in the validated measure PANSS). Other outcomes are "much" or "very much improved" on Clinical Global Impression - Improvement scale (CGI-I) and change in Personal and Social Performance Scale measuring overall disability.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Örebro, Sweden, 70116
- Region Örebro Län
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria (Swedish citizens):
- patient ages 18 to 40 years
- a duration of illness exceeding 2 years
- correspond to "Markedly ill", "Severely ill" or "Among the most extremely ill patients" on the Clinical Global Impression - Severity scale (CGI-S)
- Global Assessment of Functioning below 50
- Schizophrenia spectrum disorder according to The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
- treatment resistance, i.e. failing to remit despite adequate treatments
- if female and with any risk for pregnancy, willing to use contraceptives
- if antipsychotic treatment is prescribed the plasma concentrations of the drug must be tested and shown to be within therapeutic interval.
- subjects should be judged by the investigator to be lucid and oriented to person, place, time, and situation when giving the informed consent.
- immunoglobulin levels within the normal range
Exclusion Criteria:
- on-going immunomodulatory treatment
- pregnancy or breast-feeding
- weight below 40 kg
- clinically relevant on-going infection
- chronic infections
- positive screening test for hepatitis B, C, HIV or tuberculosis
- any change of psychotropic medication within the previous 4 weeks
- "much" or "very much improved" already at baseline according to CGI-I i.e. scores of 1 or 2 by the clinician
- severe heart failure (NYHA grade IV) or other severe heart disease or history of cardiac arrhythmia or myocardial infarction
- unable to make an informed decision to consent to the trial
- in compulsory treatment
- treatment with clozapine within the last 2 months
- previous treatments with immunosuppressive agents
- malignancy currently or within 2 years prior to inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Syndrome Scale (PANSS)
Time Frame: week 20
|
Change in symptoms measured as change in Positive and Negative Syndrome Scale (PANSS) score from baseline.
PANSS measures symptom severity of patients with schizophrenia and is a clinically based interview.
PANSS measures positive symptoms (7 items, range 7-49), which refer to e.g.
hallucinations and delusions; negative symptoms (e.g.
loss of normal functions) (7 items, range 1-7) and general disability (16 Items, range 16 -112) separately.
Higher scores denote more symptoms and disability.
PANSS total score range from 30-210.
At least 40 % reduction in PANSS total score is regarded as response.
|
week 20
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Personal and Social Performance Scale (PSP)
Time Frame: week 20
|
Personal and Social Performance Scale (PSP) gives a score for disability.
The PSP is a 100-point single-item rating scale (range 1-100), subdivided into 10 equal intervals.
Lower scores denote lower functioning.
The ratings are based mainly on the assessment of patient's functioning in four main areas: 1) socially useful activities; 2) personal and social relationships; 3) self-care; and 4) disturbing and aggressive behaviours.
Change in score between enrolment and week 20 will be measured.
|
week 20
|
Clinical Global Impression-Severity (CGI-S) scale
Time Frame: week 20
|
CGI-S is a clinician rated measure of overall clinical severity that is rated on a scale between 1 and 7. A person with no clinical complaints or problems will get a score of 1.
The score 7 indicates the highest level of severity is phrased as "Among the most extremely ill patients".
|
week 20
|
Clinical Global Impression-Improvement (CGI-I) in relation to inflammatory markers
Time Frame: week 20
|
Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Change in inflammatory markers in blood (gene expression and proteins) towards normality, in relation to clinical response will be measured.
|
week 20
|
Clinical Global Impression-Improvement (CGI-I). Proportion of responders.
Time Frame: week 20
|
Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Three different informants base their CGI-I evaluations on independent assessments: a) The treating clinician, b) The patient's self-assessment and c) A next of kin.
If the mean value of these three is below 2.5 then the patient will be regarded as a responder (representing much or very much improved since baseline).
|
week 20
|
Clinical Global Impression-Improvement (CGI-I).
Time Frame: week 20
|
Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Three different informants base their CGI-I evaluations on independent assessments: a) The treating clinician, b) The patient's self-assessment and c) A next of kin.
Range 3-21.
A lower score depicts larger improvement.
|
week 20
|
Adverse event: Any Adverse Reactions (AAR). Safety and tolerability of rituximab
Time Frame: week 20
|
Any Adverse reactions (AAR) is a rating scale developed for this study and is not a validated questionnaire.
It consists of a list of 26 symptoms.
AAR maps adverse events related to rituximab treatment.
These items are assessed for severity on a Likert scale (4 levels: none; mild; moderate; severe) and frequency (3 levels: occasionally; daily; several times daily).
AAR is assessed by the clinician.
An adverse event scale was required as an outcome measure by the Swedish Medical Products Agency.
|
week 20
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Positive and Negative Syndrome Scale (PANSS)
Time Frame: week 40
|
Change in symptoms measured as change in Positive and Negative Syndrome Scale (PANSS) score from baseline.
PANSS measures symptom severity of patients with schizophrenia and is a clinically based interview.
PANSS measures positive symptoms (7 items, range 7-49), which refer to e.g.
hallucinations and delusions; negative symptoms (e.g.
loss of normal functions) (7 items, range 1-7) and general disability (16 Items, range 16 -112) separately.
Higher scores denote more symptoms and disability.
PANSS total score range from 30-210.
At least 40 % reduction in PANSS total score is regarded as response.
|
week 40
|
Personal and Social Performance Scale (PSP)
Time Frame: week 40
|
Personal and Social Performance Scale (PSP) gives a score for disability.
The PSP is a 100-point single-item rating scale (range 1-100), subdivided into 10 equal intervals.
Lower scores denote lower functioning.
The ratings are based mainly on the assessment of patient's functioning in four main areas: 1) socially useful activities; 2) personal and social relationships; 3) self-care; and 4) disturbing and aggressive behaviours.
Change in score between enrolment and week 40 will be measured.
|
week 40
|
Clinical Global Impression-Severity (CGI-S) scale
Time Frame: week 40
|
Clinical Global Impression-Severity (CGI-S) scale is a clinician rated measure of overall clinical severity that is rated on a scale between 1 and 7. A person with no clinical complaints or problems will get a score of 1.
The score 7 indicates the highest level of severity is phrased as "Among the most extremely ill patients".
|
week 40
|
Clinical Global Impression-Improvement (CGI-I) in relation to inflammatory markers
Time Frame: week 40
|
Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Change in inflammatory markers in blood (gene expression and proteins) towards normality, in relationship to clinical response Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Change in inflammatory markers in blood (gene expression and proteins) towards normality, in relation to clinical response (assessed by the clinician) will be measured.
|
week 40
|
Changes in cognitive functioning
Time Frame: week 20
|
The clinical assessment includes four sections of the Wechsler intelligence scales for adults (WAIS-IV); block design (range 1-19), letter number sequencing (range 1-19), digit symbol coding (range 1-19), and digit span (range 1-19).
A full scale IQ of each participant will be estimated using the mean of the four scaled scores available and multiplying them by 11.
A higher score denotes a cognitive improvement.
|
week 20
|
Clinical Global Impression-Improvement (CGI-I).
Time Frame: week 40
|
Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Three different informants base their CGI-I evaluations on independent assessments: a) The treating clinician, b) The patient's self-assessment and c) A next of kin.
If the mean value of these three is below 2.5 then the patient will be regarded as a responder (representing much or very much improved since baseline).
Range 3-21.
A lower score depicts larger improvement.
|
week 40
|
B-cell subpopulations in relation to clinical response
Time Frame: week 20
|
B-cell depletion at week 5, and B-cell subpopulations at week 20 in relation to clinical response (CGI-I) (assessed by the clinician) and baseline levels of B-cells.
|
week 20
|
Life quality measured with Brunnsviken Brief Quality of Life Scale (BBQ)
Time Frame: week 40
|
BBQ is a 12-item self-rated measurement of life satisfaction.
BBQ is a Likert scale, range 0-48.
Higher scores denote higher life satisfaction.
|
week 40
|
Clinical Global Impression-Improvement (CGI-I). Proportion of responders.
Time Frame: week 40
|
Clinical Global Impression-Improvement scale (CGI-I) measures change of symptoms on a 7 point Likert scale.
A CGI-I score of 1 or 2 corresponds to be much or very much improved.
Three different informants base their CGI-I evaluations on independent assessments: a) The treating clinician, b) The patient's self-assessment and c) A next of kin.
If the mean value of these three is below 2.5 then the patient will be regarded as a responder (representing much or very much improved since baseline).
|
week 40
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susanne Bejerot, Region Örebro Län
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT Number: 2018-004618-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia Spectrum and Other Psychotic Disorders
-
VA Office of Research and DevelopmentCompletedSchizophrenia Spectrum & Other Psychotic DisordersUnited States
-
New York State Psychiatric InstituteTemple University; The Zucker Hillside Hospital; Feinstein Institutes for Medical...Not yet recruitingSchizophrenia | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic Disorder
-
University of North Carolina, Chapel HillNorth Carolina Department of Health and Human ServicesCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Laval UniversityCompletedSchizophrenia and Schizophrenia Spectrum PsychosisCanada
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorders | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)CompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Unspecified Schizophrenia Spectrum and Other Psychotic Disorder | Brief Psychotic DisorderUnited States
-
Columbia UniversityNational Institute of Mental Health (NIMH)RecruitingSchizophrenia | Schizo Affective Disorder | Delusional Disorder | Schizophreniform Disorders | Other Specified Schizophrenia Spectrum and Other Psychotic DisorderUnited States
-
Psychiatric Hospital of the University of BaselActive, not recruitingHarm Reduction | Schizophrenia and Other Psychotic DisordersSwitzerland
-
Stanford UniversityCompletedPsychotic Disorders | Schizophrenia Spectrum DisordersUnited States
-
University of California, Los AngelesCompletedSchizophrenia Spectrum
Clinical Trials on Rituximab
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingEBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAnn Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
PfizerCompletedRheumatoid ArthritisUnited States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
-
Mabion SAParexelWithdrawn
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaUnited States